Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.

Marcum ZA, Driessen J, Thorpe CT, Donohue JM, Gellad WF

The Annals of pharmacotherapy16 Dec 2014Cited by 8 (Europe PMC)

PMID25515869PMCIDPMC4876962DOI10.1177/1060028014563951PepBankPUB-25515869

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneObservational studyOther
Among Medicare Part D beneficiaries aged 65 or older who filled an antidiabetic prescription, 1.6% filled a prescription for exenatide or liraglutide.
In plain wordsAmong older Medicare Part D beneficiaries who filled a diabetes prescription, a small share filled one for exenatide or liraglutide.
Peptide
Liraglutide
Outcome
Not applicableUse of exenatide or liraglutide
Study
n = 238,499
Outcome group
Patterns of use · Whole body
Measurements
Beneficiaries filling exenatide or liraglutide
1.6%
Medicare Part D beneficiaries
Source sentences
Summary
3718 (1.6%) for exenatide or liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a cross-sectional analysis of 2009-2010 claims data from a nationally representative sample of 238 499 Medicare Part D beneficiaries aged ≥65 years, who were continuously enrolled in fee-for-service Medicare and Part D and filled ≥1 antidiabetic prescription.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2551586901
02HumanNot a test of Liraglutide aloneObservational studyOther
Among older Medicare Part D beneficiaries, use of incretin mimetics as a class varied more than 3-fold across hospital-referral regions.
In plain wordsAmong older Medicare beneficiaries, use of this drug class differed more than 3-fold between regions.
Peptide
Liraglutide
Outcome
Not applicableRegional variation in incretin mimetic use
Study
n = 238,499
Outcome group
Patterns of use · Whole body
Source sentences
Summary
The adjusted proportion of beneficiaries using IMs varied more than 3-fold across HRRs, from 5th and 95th percentiles of 5.2% to 17.0%.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a cross-sectional analysis of 2009-2010 claims data from a nationally representative sample of 238 499 Medicare Part D beneficiaries aged ≥65 years, who were continuously enrolled in fee-for-service Medicare and Part D and filled ≥1 antidiabetic prescription.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2551586902
03HumanNot a test of Liraglutide aloneObservational studyOther
Among older Medicare Part D beneficiaries, users of incretin mimetics as a class had higher annual plan and patient costs for antidiabetic prescriptions than non-users.
In plain wordsAmong older Medicare beneficiaries, users of this drug class had higher yearly drug costs than non-users.
Peptide
Liraglutide
Outcome
Not applicableCosts of incretin mimetic users
Study
n = 238,499
Comparator
Non-IM users
Outcome group
Patterns of use · Whole body
Source sentences
Summary
Compared with non-IM users, IM users faced a 155% higher annual Part D plan ($1067 vs $418) and 144% higher patient ($369 vs $151) costs for antidiabetic prescriptions.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a cross-sectional analysis of 2009-2010 claims data from a nationally representative sample of 238 499 Medicare Part D beneficiaries aged ≥65 years, who were continuously enrolled in fee-for-service Medicare and Part D and filled ≥1 antidiabetic prescription.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2551586903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.